Combination BRAF-directed therapy and immunotherapy

BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)

  1. Introduction
  2. Rationale for combination BRAF-directed therapy and immunotherapy
    • Limitations of BRAF-directed therapy
    • Limitations of immunotherapy
    • Effects of BRAF inhibition on the tumor microenvironment and immune system
      • Pre-clinical studies
      • Clinical evidence
      • Murine models
  3. Ongoing clinical trials
  4. Summary of responses and toxicity to date
  5. Future directions
  6. References

[contact-form-7 id=»5168″ title=»Контактная форма 1″]


Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *